now for some maths..., page-2

Matt,

Thanks for the delivery.
One broker says this:

"The Phase III trials, approvals process and completion
of work on a sustained-delivery mechanism will
require additional capital.

The company’s preferred course of action is to strike a royalty deal with one of the world’s major pharmaceutical companies.

Based on past experience with bringing new drugs to
market, capital of at least A$25-30 million may be
required to bring Melanotan into commercial
production".
___________________________

I concur with his thinking.
What the royalty deal could be, I don't know. Just now the delivery studies have not yet been completed. There will be a lot of negotiation to do including who is to manufacture the compound.

The Melanotan supply to the world will be a staged one and will take some time.

Nevertheless you have illustrated that EPT's drug Melanotan could be a very valuable one:

http://www.hotcopper.com.au/post_thread.asp?fid=1&tid=48136#118508

http://www.hotcopper.com.au/post_thread.asp?fid=1&tid=49946#124072


Gerry